PT-141 (bremelanotide) for low desire: what's approved and what isn't

PT-141, sold as bremelanotide under the brand name Vyleesi, is FDA approved for one group only: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). In that group, trials showed modest improvements in desire and less distress about low desire. It acts on melanocortin receptors in the brain rather than on blood flow, so it is a desire medication, not an erection medication, and any use in men is off-label.

That distinction matters because PT-141 often shows up in searches for "sexual health therapy" next to erectile dysfunction treatments. They solve different problems. Below is what the FDA label actually says, where the evidence stops, and how PT-141 compares with the treatments urology guidelines recommend first.

What bremelanotide is and how it works

Bremelanotide is a synthetic peptide that activates melanocortin receptors, a family of receptors involved in appetite, pigmentation and sexual behavior. According to the FDA Vyleesi label on DailyMed, it is a melanocortin receptor agonist that binds most strongly to the MC4 receptor at therapeutic doses, and the exact way it improves sexual desire is not known.

What is clear is where it works: the central nervous system. It does not dilate blood vessels in the genitals the way erectile dysfunction pills do. Think of it as acting on the "wanting" side of sexual function rather than the mechanical side.

That is also why it is not a hormone. PT-141 does not raise testosterone or estrogen, and it does not correct a hormone deficiency. If low desire is driven by low testosterone, thyroid problems, medication side effects or depression, PT-141 does not address the cause.

FDA approval: Vyleesi for premenopausal women with acquired HSDD

The FDA approved Vyleesi in 2019. The label is narrow and specific. It is indicated for premenopausal women with acquired, generalized HSDD, meaning low desire that:

The label states it is not indicated for postmenopausal women or men, and not to enhance sexual performance.

Here is how the approved product is used, per the DailyMed label:

Label detail What it says
Form 1.75 mg subcutaneous autoinjector, in the abdomen or thigh
Timing As needed, at least 45 minutes before anticipated sexual activity
Maximum use No more than 1 dose in 24 hours; no more than 8 doses per month
When to stop After 8 weeks if there is no improvement in desire and related distress
Who should not use it People with uncontrolled high blood pressure or known cardiovascular disease

On effectiveness, be realistic. In the trials summarized in the label, women on bremelanotide reported improvements in desire scores and reductions in distress compared with placebo, but the differences were modest. The label also reports no meaningful difference from placebo in the number of satisfying sexual events. For some women that change in desire is worthwhile; for others it is not enough to justify the side effects.

Use in men: off-label, with limited evidence

There is no FDA approval for bremelanotide in men, for low libido or for erectile dysfunction. The phase 3 trials that supported Vyleesi enrolled premenopausal women, so the evidence base behind the approved dose, safety warnings and dosing limits comes from women.

Evidence in men is limited and was not the basis for any approval. That does not mean it never has an effect in men; it means you cannot point to a body of large, controlled trials showing how well it works, at what dose, or how safe repeated use is. Men who use PT-141 are using it off-label, and the blood pressure warnings on the label are especially relevant because cardiovascular disease is common in the same age groups that seek help for sexual function.

If you are a man with low desire, the evaluation usually starts elsewhere. Low testosterone, poor sleep, high stress, depression, certain medications and relationship factors are all common contributors. A testosterone and metabolic workup, like the one used in BioCure's hormone optimization program, answers a basic question first: is there a measurable, treatable cause?

Side effects: nausea, flushing, blood pressure and skin darkening

The FDA label lists a clear set of risks. These are the ones to know before considering it:

Side effect What the label describes
Nausea The most common side effect in trials; most often with the first dose, and a frequent reason people stopped
Flushing Common, usually shortly after the injection
Injection site reactions and headache Commonly reported
Blood pressure and heart rate A temporary rise in blood pressure and drop in heart rate after each dose
Focal hyperpigmentation Darkening of the skin, including the face, gums and breasts; more likely with frequent dosing and may not fully resolve after stopping
Drug interaction Can significantly lower levels of oral naltrexone, a medication used for alcohol and opioid dependence

The blood pressure effect is the reason for the contraindication in uncontrolled hypertension and known cardiovascular disease, and why the label caps use at eight doses a month. The skin darkening reflects the same melanocortin system that controls pigmentation. Anyone with heart disease, high blood pressure, or a history of pigment problems should talk this through with a physician before using it.

How PT-141 differs from PDE5 inhibitors

PDE5 inhibitors, the class that includes sildenafil and tadalafil, are the treatment most people mean when they search for erectile dysfunction options. The EAU guidelines on management of erectile dysfunction place lifestyle and risk factor changes alongside PDE5 inhibitors as first-line care, with vacuum devices, penile injections and implants as further steps, and psychosexual therapy as part of treatment. The American Urological Association's erectile dysfunction guideline similarly covers evaluation and a full range of treatment options, including PDE5 inhibitors.

PT-141 does not appear in that ED treatment sequence, because it does not act on the erection mechanism.

PT-141 (bremelanotide) PDE5 inhibitors
Main target Desire and arousal pathways in the brain Blood flow in erectile tissue
FDA approved for Acquired, generalized HSDD in premenopausal women Erectile dysfunction in men
Needs sexual stimulation to work Acts centrally; does not create an erection mechanically Yes; enhances the natural response to stimulation
Form Subcutaneous injection Oral tablet
Key safety concerns Nausea, blood pressure rise, skin darkening Must not be combined with nitrates; headache, flushing, nasal congestion
Place in guidelines for ED Not a guideline ED treatment First-line drug option

The practical takeaway: if the problem is getting or keeping an erection, PDE5 inhibitors and the steps in the EAU and AUA guidelines are the evidence-based path. If the problem is a genuine loss of desire, PT-141 is one option in a narrow approved group, and the cause still needs to be looked for. The Cleveland Clinic also notes that sex therapy is a recognized part of sexual health treatment; the AASECT directory lists certified sex therapists if relationship or psychological factors are part of the picture. If you prefer in-person urology care where you live, a local urologist or sexual medicine clinic can run the same guideline-based evaluation.

Compounded PT-141: what "available online" really means

You will see PT-141 sold as nasal sprays, vials and lozenges, often through online clinics or "research peptide" websites. Two points matter here.

First, the only FDA-approved bremelanotide product is Vyleesi, the autoinjector described above. Compounded versions made by pharmacies are not FDA approved, which means the FDA has not reviewed them for safety, effectiveness or manufacturing quality, and doses and forms like nasal sprays have not been through the trials behind the approved label. Licensed compounding pharmacies are regulated, but that is different from FDA approval of the product.

Second, "research use only" peptides sold directly to consumers are not intended for human use at all. Purity, dose and sterility are unknown.

If you are considering PT-141 in any form, it should be prescribed by a clinician who has reviewed your blood pressure, heart history and current medications, including naltrexone.

Where BioCure fits

BioCure Health is a physician-led telehealth clinic based in the Fort Lauderdale area, licensed to treat patients in 47 states. Our peptide therapy is physician-guided and lab-driven: every protocol starts with an evaluation and blood work, not a product order. PT-141 is not one of the protocols listed on our peptide page, so whether a desire-focused peptide makes sense for you is a question for your consultation, answered against your labs and health history rather than assumed.

We also treat sexual health concerns, including erectile dysfunction, and evaluate hormones through our comprehensive panels. For men, that often means checking testosterone before anything else. The process is a short online intake, a $199 physician video consultation that can be credited toward a membership, testing at home or in a lab with results in 7 to 14 days, and a 1:1 review of your protocol. BioCure does not bill insurance directly, but many patients use HSA or FSA funds, and we provide documentation for reimbursement. For background, our earlier overview of PT-141 covers the basics; this article reflects the current FDA label.

Frequently asked questions

Is PT-141 FDA approved?

Yes, but only in one form and for one group. Bremelanotide is FDA approved as Vyleesi, an injection for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not approved for men, postmenopausal women, or to enhance sexual performance.

Does PT-141 work for men?

Use in men is off-label, and the evidence is limited compared with the trials in women that led to approval. It acts on desire pathways in the brain rather than blood flow, so it is not a substitute for guideline-based erectile dysfunction treatment. Men with low desire should have testosterone and other causes checked first.

Is PT-141 better than Viagra?

They treat different problems. PDE5 inhibitors like sildenafil improve blood flow for erections and are a first-line ED treatment in urology guidelines. PT-141 targets desire in the brain and is approved only for HSDD in premenopausal women.

What are the side effects of PT-141?

The FDA label lists nausea as the most common side effect, along with flushing, headache and injection site reactions. It causes a temporary rise in blood pressure after each dose and can darken the skin, especially with frequent use. People with uncontrolled hypertension or known cardiovascular disease should not use it.

Is compounded PT-141 nasal spray safe?

Compounded PT-141, including nasal sprays, is not FDA approved, so its safety, dose accuracy and effectiveness have not been reviewed by the FDA. The approved product is an injection. "Research use only" peptides sold online are not meant for human use.

Low desire is real, common and worth taking seriously, but it rarely has a single cause or a single fix. Start with the evidence, check what is measurable, and choose treatment based on what is actually driving the problem.

Let BioCure Health lead you in the right direction. Call or text us to schedule an introductory call at 754-206-0838, your future self will thank you.